C Singer

434 total citations
15 papers, 314 citations indexed

About

C Singer is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, C Singer has authored 15 papers receiving a total of 314 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 8 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in C Singer's work include Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (4 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). C Singer is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Cancer Treatment and Pharmacology (4 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). C Singer collaborates with scholars based in Austria, Canada and United States. C Singer's co-authors include Vesna Bjelic‐Radisic, Peter Schrenk, A. Fink-Retter, Mohamed Salama, Daphne Gschwantler‐Kaulich, Andrea Eisen, Susan L. Neuhausen, Steven A. Narod, Swen Langer and Catherine M. Phelan and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

C Singer

14 papers receiving 308 citations

Peers

C Singer

ONCOL

GENET

SURGE

Marie Stenmark Askmalm Sweden

Bernard Lespérance Canada

So Young Kang South Korea

Sue Gerty United Kingdom

Sarah Benafif United Kingdom

Vida Stegel Slovenia

Susanna Aussó Spain

Amal Yussuf United States

Marilee McGinness United States

Maria Angela Bella Italy

Marie Stenmark Askmalm Sweden

C Singer

148 ×1.2

ONCOL

141 ×1.5

108 ×1.2

91 ×1.1

GENET

136 ×1.7

SURGE

Citations per year, relative to C Singer C Singer (= 1×) peers Marie Stenmark Askmalm

Countries citing papers authored by C Singer

Since Specialization

Citations

This map shows the geographic impact of C Singer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C Singer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C Singer more than expected).

Fields of papers citing papers by C Singer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C Singer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C Singer. The network helps show where C Singer may publish in the future.

Co-authorship network of co-authors of C Singer

This figure shows the co-authorship network connecting the top 25 collaborators of C Singer. A scholar is included among the top collaborators of C Singer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C Singer. C Singer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Singer, C, Daniel Egle, Leopold Oehler, et al.. (2025). 356P Real-world (RW) outcomes with first-line (1L) ribociclib (RIB)+endocrine therapy (ET) in patients (pts) with HR+, HER2– metastatic breast cancer (MBC): Final analysis of the phase IV REACH AUT study. ESMO Open. 10. 104927–104927.

Bartsch, Rupert, Anna S. Berghoff, Julia Furtner, et al.. (2024). 187P Stage I results of a phase II study of datopotamab deruxtecan (DATO-DXd) in triple-negative breast cancer (TNBC) patients (pts) with active brain metastases (TUXEDO-2). ESMO Open. 9. 103209–103209. 4 indexed citations

Chan, Arlene, Manuel Ruíz Borrego, Gavin Marx, et al.. (2022). 73P Effect of diarrheal prophylaxis or dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Final findings from the CONTROL trial. Annals of Oncology. 33. S156–S156. 1 indexed citations

Tutt, Andrew, John J. Garber, R.D. Gelber, et al.. (2022). VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer. Annals of Oncology. 33(5). 566–568. 26 indexed citations

Bartsch, Rupert, Anna S. Berghoff, Julia Furtner, et al.. (2022). 165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial. Annals of Oncology. 33. S198–S198. 14 indexed citations

Singer, C, Daniel Egle, Richard Greil, et al.. (2022). 195P REACH AUT: Efficacy and safety of first-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) from a real-world (RW) study: 3rd interim analysis. Annals of Oncology. 33. S217–S217. 2 indexed citations

Bjelic‐Radisic, Vesna, Florian Fitzal, Michael Knauer, et al.. (2020). Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial. BMC Cancer. 20(1). 392–392. 24 indexed citations

Tan, Yen Y., et al.. (2018). Patient satisfaction after breast cancer surgery – a prospective clinical trial. Geburtshilfe und Frauenheilkunde. 2 indexed citations

Schrenk, Peter, et al.. (2017). Mesh versus acellular dermal matrix in immediate implant based breast reconstruction – a prospective randomized trial. European Journal of Cancer. 72. S30–S30. 11 indexed citations

10.

Gschwantler‐Kaulich, Daphne, Peter Schrenk, Vesna Bjelic‐Radisic, et al.. (2016). Mesh versus acellular dermal matrix in immediate implant-based breast reconstruction – A prospective randomized trial. European Journal of Surgical Oncology. 42(5). 665–671. 59 indexed citations

11.

Singer, C, et al.. (2014). COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component. Bratislavské lekárske listy/Bratislava medical journal. 115(7). 445–451. 8 indexed citations

12.

Phelan, Catherine M., Javaid Iqbal, Henry T. Lynch, et al.. (2013). Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. British Journal of Cancer. 110(2). 530–534. 102 indexed citations

13.

Gnant, Michael, Martin Filipits, Brigitte Mlineritsch, et al.. (2012). Abstract P2-10-02: Clinical validation of the PAM50 risk of recurrence (ROR) score for predicting residual risk of distant-recurrence (DR) after endocrine therapy in postmenopausal women with ER+ early breast cancer (EBC): An ABCSG study. Cancer Research. 72(24_Supplement). P2–10. 10 indexed citations

14.

Fink-Retter, A., Daphne Gschwantler‐Kaulich, C Singer, et al.. (2008). Proteomics in mammary cancer research. Journal of Clinical Oncology. 26(15_suppl). 22206–22206. 1 indexed citations

15.

Langer, Swen, C Singer, Gernot Hudelist, et al.. (2006). Jun and Fos family protein expression in human breast cancer: correlation of protein expression and clinicopathological parameters.. PubMed. 27(4). 345–52. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact